Florida football cornerback Dijon Johnson was arrested in Tampa on four counts, including felony drug and weapons charges ...

A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser ...

The FDA has approved Johnson & Johnson’s drug Imaavy for the treatment of generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder. The approval covers adults and pediatric patients ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

The US FDA has approved Johnson & Johnson’s drug to treat patients aged 12 years and older with an immune-mediated disorder ...

IMAAVY TM (nipocalimab-aahu) is a first-in-class FcRn (neonatal Fc receptor) inhibitor, designed to reduce the levels of ...

Johnson & Johnson recently experienced a 3% price increase in the last quarter, a period during which significant developments occurred for the company. Notably, the FDA granted approval for ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...